The study is testing the safety and effectiveness of an experimental drug called VE303-002 for preventing recurrence of C Diff. VE303 is a preparation of 8 different types of bacteria grown in clean conditions, dried, powdered, and put into capsules. The bacteria are activated once they reach the intestines.
Criteria:- Have an active of C Diff
- Have not been on antibiotic treatment for more than 72 hours and fall into 1 of these 3 categories (a, b, or c):
a) You are at least 18 years of age and have experienced a prior episode of C Diff within the last 6 months
OR
b) You are between ages 65 and 74 (inclusive) with or without prior episodes C Diff who exhibit one or more of the following risk factors for recurrence:
i) Have kidney dysfunction (further evaluation by study doctor will be required)
ii) Have a history of regular use of Proton Pump Inhibitors such as Omeprazole, pantoprazole, etc within the past 2 months and will be continuing use of PPIs throughout the study
iii) Have a History of C Diff at any time
OR
c) You are at least 75 years of age and are experiencing an active episode of C Diff